(-)-terconazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (-)-terconazole
• 英文别名: terconazole；1-{4-[[2-(2,4-dichlorophenyl)r-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-c-4-yl]methoxy]-phenyl}-4-isopropylpiperazine；Triaconazole；1-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine
• 化学式: C₂₆H₃₁Cl₂N₅O₃
• 分子量: 532.47
• InChiKey: BLSQLHNBWJLIBQ-ZEQKJWHPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  64.9
• 氢给体数：
  0
• 氢受体数：
  7

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：阴道特康唑在哺乳期尚未进行研究。其他抗真菌药物可能更受欢迎，特别是在哺乳新生儿或早产儿时。 ◉ 对哺乳婴儿的影响：截至修订日期，未找到相关的已发布信息。 ◉ 对泌乳和母乳的影响：截至修订日期，未找到相关的已发布信息。

◉ Summary of Use during Lactation:Vaginal terconazole has not been studied during breastfeeding. Other antifungal agents may be preferred, especially while nursing a newborn or preterm infant ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

反应信息

• 作为产物：
  描述：

  (+/-)-cis-[2-(bromomethyl)-2-(2,4-dichlorophenyl)-1,3-dioxolane-4-yl]methyl benzoate 在 吡啶 、 sodium hydroxide 、 sodium hydride 作用下， 以 1,4-二氧六环 为溶剂， 反应 41.0h， 生成 (-)-terconazole
  参考文献：
  名称：

  Stereoselective syntheses of (+)- and (−)-terconazole

  摘要：

  The recently described cis-benzoates (2R,4R)- and (2S,4S)-2 were transformed into (+)- and (-)-terconazole, respectively, by reaction with 1H-1,2,4-triazole followed by hydrolysis to give alcohols (+)- and (-)-3 which were mesylated and reacted with phenol 5. The ee's of (+)-and(-)-terconazole determined by HPLC on the CSP Chiralcel OD-H were > 99%.

  DOI：

  10.1016/0957-4166(95)00313-e

文献信息

• Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
  申请人：——

  公开号：US20020119989A1

  公开（公告）日：2002-08-29

  The present invention relates to chemical compounds having inhibitory activity on an intermediate conductance Ca 2+ activated potassium channel (IK Ca), and the use of such compounds for the treatment or alleviation of diseases or conditions relating to immune dysfunction. Moreover, the invention relates to a method of screening a chemical compound for inhibitory activity on an intermediate conductance Ca 2+ activated potassium channel (IK Ca).

  本发明涉及具有对中间电导性Ca2+激活钾通道（IK Ca）具有抑制活性的化合物，以及利用这种化合物治疗或缓解与免疫功能紊乱相关的疾病或症状。此外，本发明涉及一种筛选化合物对中间电导性Ca2+激活钾通道（IK Ca）具有抑制活性的方法。
• Terconazole composition and method
  申请人：Curatek Pharmaceuticals Holding, Inc.

  公开号：US10398692B2

  公开（公告）日：2019-09-03

  An aqueous terconazole composition comprises at least about 0.4 percent by weight of terconazole dissolved in water, and a terconazole crystallization-inhibiting amount of citric acid. The composition is free from terconazole crystals at an ambient temperature of about 20° C. Methods of preparing the composition are also described. The compositions provide for improved therapeutic release of terconazole.

  一种水性特康唑组合物包含至少约 0.4%（按重量计）溶于水的特康唑，以及特康唑结晶抑制量的柠檬酸。还描述了制备组合物的方法。这些组合物改善了特康唑的治疗释放。
• Method for the treatment of bladder cancer
  申请人：Cipla Limited

  公开号：US11207319B2

  公开（公告）日：2021-12-28

  Methods of treating bladder cancer using terconazole are disclosed herein. Terconazole can be administered as part of a comprehensive treatment program, which can also include chemotherapy, immunotherapy, radiation therapy and/or surgical treatment.

  本文公开了使用特康唑治疗膀胱癌的方法。特康唑可作为综合治疗方案的一部分进行施用，综合治疗方案还可包括化疗、免疫治疗、放射治疗和/或手术治疗。
• CHEMICAL COMPOUNDS HAVING ION CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OF IMMUNE DYSFUNCTION
  申请人：NEUROSEARCH A/S

  公开号：EP1052990A2

  公开（公告）日：2000-11-22
• VERWENDUNG VON AZOLEN ZUR PRÄVENTION VON STRAHLEN-INDUZIERTEM HAUTKREBS
  申请人：Bayer HealthCare AG

  公开号：EP1244445B1

  公开（公告）日：2005-08-31